# Non-Interventional Study on the Tolerability and Efficacy of IVIG

> **NCT02303093** · — · COMPLETED · sponsor: **Octapharma** · enrollment: 344 (actual)

## Conditions studied

- Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG

## Interventions

- **BIOLOGICAL:** Octagam IVIG 5% or 10%
- **BIOLOGICAL:** Panzyga

## Key facts

- **NCT ID:** NCT02303093
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-01
- **Primary completion:** 2020-06-05
- **Final completion:** 2020-06-05
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2021-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02303093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02303093, "Non-Interventional Study on the Tolerability and Efficacy of IVIG". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02303093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*